Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Apr 8;10(2):00741-2023.
doi: 10.1183/23120541.00741-2023. eCollection 2024 Mar.

As-needed low-dose inhaled corticosteroid/formoterol therapy in patients with severe asthma included in the German Asthma Net cohort

Christopher Alexander Hinze  1 , Rainer Ehmann  2 , Margret Jandl  3 , Katrin Milger  4 , Olaf Schmidt  5 , Christian Schulz  6 , Dirk Skowasch  7 , Tobias Welte  1 , Roland Buhl  8 , Eckard Hamelmann  9 , Marco Idzko  10 , Christian Taube  11 , Stephanie Korn  12   13 , Hendrik Suhling  1   13
Affiliations

As-needed low-dose inhaled corticosteroid/formoterol therapy in patients with severe asthma included in the German Asthma Net cohort

Christopher Alexander Hinze et al. ERJ Open Res. .

Abstract

After the GINA update in 2019, the proportion of SMART therapy increased with evidence for better disease control in SMART patients compared to SABA alone https://bit.ly/3SSPX1C.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: C.A. Hinze has nothing to disclose. Conflict of interest: R. Ehmann has nothing to disclose. Conflict of interest: M. Jandl has nothing to disclose. Conflict of interest: K. Milger reports fees for lectures or consultation from AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Novartis and Sanofi, all outside the submitted work. Conflict of interest: O. Schmidt reports fees for lectures or consultations from AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Novartis and Sanofi, all outside the submitted work. Conflict of interest: C. Schulz reports fees for lectures or consultations from AstraZeneca, Novartis and Sanofi, all outside the submitted work. Conflict of interest: D. Skowasch reports fees for lectures or consultation from AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Janssen, MSD and Sanofi, all outside the submitted work. Conflict of interest: T. Welte and/or his institution received grants advisory/lecture/clinical trial fees and non-financial support from BMBF (German Ministry of Research and Education), AstraZeneca, GSK, Sanofi Aventis and Biotest, outside the submitted work. Conflict of interest: R. Buhl reports grants to Mainz University from Boehringer Ingelheim, GSK, Novartis, and Roche, as well as personal fees from AstraZeneca, Berlin-Chemie, Boehringer Ingelheim, Chiesi, Cipla, GSK, Novartis, Roche, Sanofi and Teva, all outside the submitted work. Conflict of interest: E. Hamelmann is funded by the BMBF (CHAMP, project number 01GL1742D) for characterisation of children and adolescents with severe asthma; he reports personal fees from ALK, Boehringer Ingelheim, GSK, Leti Pharma, Novartis, Nutricia, Sanofi and Stallergenes, all outside the submitted work. Conflict of interest: M. Idzko has received fees for lectures and/or advisory board meetings from Alk Pharma, AstraZeneca, Berlin-Chemie, Chiesi, CSL-Behring, Jansen & Jansen, Menarini, Novartis, Roche, Sanofi Aventis and Teva, all outside the submitted work. Conflict of interest: C. Taube has nothing to disclose. Conflict of interest: S. Korn has received fees for lectures and/or advisory board meetings from AstraZeneca, Chiesi, GSK, Novartis, Roche, Sanofi Aventis and Teva, all outside the submitted work. Conflict of interest: H. Suhling reports fees for lectures or consultation from AstraZeneca, GSK, Novartis and Sanofi, all outside the submitted work.

Similar articles

See all similar articles

References

    1. Levy ML, Bacharier LB, Bateman E, et al. . Key recommendations for primary care from the 2022 Global Initiative for Asthma (GINA) update. NPJ Prim Care Respir Med 2023; 33: 7. doi:10.1038/s41533-023-00330-1 - DOI - PMC - PubMed
    1. Aumann I, Prenzler A, Welte T, et al. . Epidemiologie und Kosten von Asthma bronchiale in Deutschland – eine systematische Literaturrecherche [Epidemiology and costs of asthma in Germany – a systematic literature review]. Pneumologie 2014; 68: 557–567. doi:10.1055/s-0034-1377225 - DOI - PubMed
    1. Kharaba Z, Feghali E, El Husseini F, et al. . An assessment of quality of life in patients with asthma through physical, emotional, social, and occupational aspects. A cross-sectional study. Front Public Health 2022; 10: 883784. doi:10.3389/fpubh.2022.883784 - DOI - PMC - PubMed
    1. Reddel HK, FitzGerald JM, Bateman ED, et al. . GINA 2019: a fundamental change in asthma management. Eur Respir J 2019; 53: 1901046. doi:10.1183/13993003.01046-2019 - DOI - PubMed
    1. Worth H, Criée CP, Vogelmeier CF, et al. . Prevalence of overuse of short-acting beta-2 agonists (SABA) and associated factors among patients with asthma in Germany. Respir Res 2021; 22: 108. doi:10.1186/s12931-021-01701-3 - DOI - PMC - PubMed

LinkOut - more resources